Timeline

Dated events in the published records, newest first: regulatory decisions, guideline recommendations and editions, study dates from their registries and milestones that happened. Each date is shown as precisely as its record states it.

267 events. A year or a month is never shown as a day, and a year-only date sorts below the dated events of that year. 19 are registry dates that the registry does not mark as reached, so each says so. Expected future events are on the calendar. (page 3 of 3)

10,177 registry records are not listed here: a program assembled them, and a registry changes them without notice. A registry trial shows its own dates on its page. Expected registry dates are on the calendar.

2015 19

  1. Supplemental approval Empagliflozin (Jardiance)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA204629 · Where: United States

    Source: openFDA Drugs@FDA record for NDA204629: JARDIANCE (empagliflozin tablets)

  2. Supplemental approval Empagliflozin (Jardiance)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA204629 · Where: United States

    Source: openFDA Drugs@FDA record for NDA204629: JARDIANCE (empagliflozin tablets)

  3. Supplemental approval Dapagliflozin (Farxiga)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202293 · Where: United States

    Source: openFDA Drugs@FDA record for NDA202293: FARXIGA (dapagliflozin tablets)

2014 14

  1. Supplemental approval Apixaban (Eliquis)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202155 · Where: United States

    Source: FDA drug application NDA202155 (openFDA Drugs@FDA record)

  2. Supplemental approval Dabigatran (Pradaxa)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA022512 · Where: United States

    Source: FDA drug application NDA022512 (openFDA Drugs@FDA record)

  3. Supplemental approval Apixaban (Eliquis)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202155 · Where: United States

    Source: FDA drug application NDA202155 (openFDA Drugs@FDA record)

2013 6

  1. Results first posted ARISTOTLE Registry does not say if reached

    Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

2012 7

  1. Approval Apixaban (Eliquis)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA202155 · Where: United States

    Sources: FDA drug application NDA202155 (openFDA Drugs@FDA record); FDA approval letter for NDA NDA202155

2011 4

  1. Results first posted RE-LY Registry does not say if reached

    Source: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

2010 7

  1. Approval Dabigatran (Pradaxa)

    Authority: U.S. Food and Drug Administration · Pathway: NDA · Submission: NDA022512 · Where: United States

    Sources: FDA drug application NDA022512 (openFDA Drugs@FDA record); FDA approval letter for NDA NDA022512

2009 2

2008 3

2007 1

2006 2

2005 4

2003 1

2002 2

2001 2

2000 1

1997 2

  1. Study start SCD-HeFT Registry does not say if reached

    Source: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

  2. Study start DASH-Sodium Registry does not say if reached

    Source: Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)